Anti-NMDAR encephalitis (n=61) | |
Age (years, mean±SD) | 25.6±15.6 |
Age (years, n, %) | |
4–17 | 23 (37.7) |
18–44 | 28 (45.9) |
45–64 | 10 (16.4) |
Gender (female, n, %) | 31 (50.8) |
BMI (median, range) | 20.4 (8.3–30.4) |
Season | |
Spring:summer:fall:winter | 23:14:10:14 |
mRS before treatment (median, range) | 4.0 (1.0–5.0) |
mRS after the treatment* (median, range) | 2.0 (0.0–5.0) |
CSF anti-NMDAR Abs positive (n, %) | 61 (100) |
CSF pleocytosis (n, %) | 36 (59.1) |
CSF protein increase (n, %) | 14 (23.0) |
CSF virus-Abs positive (n, %) | 7 (11.5) |
HSV-1 IgG | 2 (3.3) |
HSV-1/2 IgG | 4 (6.6) |
CMV-IgG | 1 (1.6) |
Abnormal MRI (n, %) | 28 (45.9) |
With tumour (n, %) | 15 (24.6) |
Ovarian teratoma | 9 (14.8) |
Ovarian cysts | 5 (8.2) |
Colon carcinoma | 1 (1.6) |
Symptoms of signs (n, %) | |
Prodromal symptoms (fever, headache) | 28 (45.9) |
Psychiatric symptoms | 40 (65.6) |
Memory deficits | 9 (14.8) |
Speech disturbances | 21 (34.4) |
Seizures | 32 (52.3) |
Movement disorders | 24 (39.3) |
Loss of consciousness | 14 (23.0) |
Treatment (n, %) | |
First-line treatment | 33 (54.1) |
First-line combined with second-line treatment | 28 (45.9) |
Tumour removal | 12 (19.7) |
With NICU support (n, %) | 24 (39.3) |
*mRS was accessed 3 months after the treatment.
Abs, antibodies; BMI, body mass index; CMV, cytomegalovirus; CSF, cerebrospinal fluid; HSV, herpes simplex virus; NICU, neurological intensive care unit; anti-NMDAR, anti-N-Methyl-D-aspartate receptor; mRS, modified Rankin Scale.